Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
SunTrust Robinson Humphrey Downgrades Summit Therapeutics plc (SMMT) to Hold
June 27, 2018 1:51 PM EDTSunTrust Robinson Humphrey downgraded Summit Therapeutics plc (NASDAQ: SMMT) from Buy to Hold with a price target of $4.00 (from $22.00) after the company announced that the Phase II PhaseOut DMD study did not meet the pre-specified primary endpoint.
Ridinilazole, now the company's lead... More
Summit Therapeutics (SMMT) to Resumes Trading at 7:30 am ET
June 27, 2018 7:11 AM EDTSummit Therapeutics (NASDAQ: SMMT) to Resumes Trading at 7:30 am ET
... More